RESEARCH PAPER
Characterization of acute adverse-effect profi le of carbamazepine and valproate in the grip-strength test in mice
1
Department of Pathophysiology, Medical University, Lublin, Poland; Department of Physiopathology, Institute of Agricultural Medicine, Lublin, Poland
2
Department of Pathophysiology, Medical University, Lublin, Poland
3
Department of Physiopathology, Institute of Agricultural Medicine, Lublin, Poland
Corresponding author
Jarogniew J. Łuszczki
Department of Pathophysiology, Medical University, Jaczewskiego 8, 20-090 Lublin, Poland
Department of Pathophysiology, Medical University, Jaczewskiego 8, 20-090 Lublin, Poland
J Pre Clin Clin Res. 2008;2(1):46–48
KEYWORDS
carbamazepinevalproategrip-strengthdose-response relationship analysisacute adverse-eff ect profi le
ABSTRACT
The aim of this study was to assess the acute adverse (neurotoxic) effects of two conventional antiepileptic drugs (carbamazepine and valproate) in the grip-strength test by measuring skeletal muscular strength in mice. Linear regression analysis of dose-response relationship for drug doses and their corresponding skeletal muscular strength allowed the determination of the doses of carbamazepine and valproate that reduced the grip-strength in mice by 50%, as compared to control mice. The experimentally-derived strength reducing dose by 50% for carbamazepine was 80.8 mg/kg, and that for valproate – 501.2 mg/kg. Based on this preclinical study, one can conclude that carbamazepine and valproate reduced in a dose-dependent manner skeletal muscular strength in mice. The grip-strength test can be applied as a paradigm for the evaluation of acute adverse-effect (neurotoxic) profile of drugs with respect to their influence on muscular strength in experimental mice.
REFERENCES (8)
1.
Brodie MJ, Schachter SC: Fast Facts. Epilepsy (2nd ed.), Health Press: Oxford 2001.
2.
Perucca E: Pharmacological principles as a basis for polytherapy. Acta Neurol Scand Suppl 1995, 162, 31-34.
3.
Loscher W, Nolting B: The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. IV. Protective indices. Epilepsy Res 1991, 9, 1-10.
4.
Motulsky HJ, Christopoulos A: Fitting models to biological data using linear and nonlinear regression. A practical guide to curve fi tting. GraphPad Software Inc, San Diego CA, 2003.
5.
Łuszczki JJ, Andres MM, Czuczwar P, Cioczek-Czuczwar A, Wojcik- Cwikła J, Ratnaraj N, Patsalos PN, Czuczwar SJ: Levetiracetam selectively potentiates the acute neurotoxic eff ects of topiramate and carbamazepine in the rotarod test in mice. Eur Neuropsychopharmacol 2005, 15, 609-616.
6.
Łuszczki JJ, Czuczwar M, Kis J, Krysa J, Pasztelan I, Świader M, Czuczwar SJ: Interactions of lamotrigine with topiramate and fi rstgeneration antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia 2003, 44, 1003-1013.
7.
Łuszczki JJ, Czuczwar SJ: Isobolographic characterization of interactions between vigabatrin and tiagabine in two experimental models of epilepsy. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31, 529-538.
8.
Litchfi eld JT, Wilcoxon F: A simplifi ed method of evaluating dose-eff ect experiments. J Pharmacol Exp Ther 1949, 96, 99-113.
Share
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.